Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531344 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL532586 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531329 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531605 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL531606 | 1.00 | CETP (0.48) | CETPNR1I2SCN5AIKBKBAKR1C3 | |
| SCHEMBL13905492 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL17366579 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10086303 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL13905501 | 0.91 | CETP (0.43) | CETPNR1I2SCN5AIKBKBGRM5 | |
| SCHEMBL10260659 | 0.91 | CETP (0.43) | CETPNR1I2SCN5ATACR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-2985022-B1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2943474-B1 | BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXENE DERIVATIVE COMPOUNDS AS CETP INHIBITORS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-9493430-B2 | Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20160237046-A9 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2016-08-18 | — | — | US | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2985022-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20150322023-A1 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CHONG KUN DANG PHARM CORP (KR) | 2015-11-12 | — | — | US | disclosed |
| EP-1901741-B1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2009027785-A2 | 1, 3-OXAZOLE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-2029560-A2 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | Merck & Co., Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| EP-1983966-A2 | POLYMER FORMULATIONS OF CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008082567-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| WO-2007092642-A2 | POLYMER FORMULATIONS OF CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 74/4885SCN5A 2915/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | CETP 4675/4885NR1I2 944/4885SCN5A 1784/4885 |
| US-20160237046-A9 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CETP, LIPC, PCSK9 | CETP 1/4885NR1I2 83/4885SCN5A 2875/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885SCN5A 3597/4885 |
| US-20150322023-A1 | Biaryl- or Heterocyclic Biaryl-Substituted Cyclohexene Derivative Compounds as CETP Inhibitors | CETP, LIPC, PCSK9 | CETP 1/4885NR1I2 83/4885SCN5A 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.